Blank Rome partner Merle M. DeLancey, Jr. will serve as a presenter for Rx Drug Pricing & Rebate Fundamentals, an American Conference Institute (“ACI”) Virtual Proficiency Series program being held November 2 through December 2, 2026.

About the Program

ACI’s Rx Drug Pricing & Rebate Fundamentals provides intensive training for both emerging and experienced government payor professionals in essential drug pricing and rebate concepts, methodologies, and strategies across key government payor programs.

Sessions will be held two days a week over the course of four weeks and examine:

  • Drug Pricing and Rebate Essentials and Introduction to Medicaid
  • PHS 340B, VA, and DoD Rx Pricing and Rebates
  • Medicare Pricing and Rebate Essentials and Advanced CMS Pricing and Rebate Topics
  • New Product Launches, Emerging Commercial Models, and Strategic Financial Planning

Merle’s session, “What You Need to Know About State Prescription Drug Affordability Boards,” will be held on Wednesday, November 4, from 4:00 to 4:45 p.m. EST.

About the Session

Prescription Drug Affordability Boards (“PDABs”) are state-established bodies that evaluate the affordability of high-cost prescription drugs. Their powers vary by state and may include conducting affordability reviews, issuing nonbinding recommendations, and, in some cases, establishing binding Upper Payment Limits (“UPLs”) to cap drug prices or reimbursements. PDABs are similarly proliferating across the country and pose a real risk of creating a pricing and reimbursement landscape that varies state-by-state. This session will:

  • Clarify the role of PDABs
  • Survey states with PDABs and those with pending legislation
  • Identify PDABs with UPL authority
  • Review PDAB litigation to date

Speakers:

  • Merle M. DeLancey, Jr., Partner, Blank Rome LLP
  • Andrew York, Executive Director, Maryland Prescription Drug Affordability Board

For more information and to register, please visit the event webpage.